ReAlta signs deal with NIAID to develop drug for radiation poisoning
US-based pharma company ReAlta Life Sciences has teamed up with the US National Institute of Allergy and Infectious Diseases (NIAID)…
US-based pharma company ReAlta Life Sciences has teamed up with the US National Institute of Allergy and Infectious Diseases (NIAID)…
Gilead Sciences and Xilio Therapeutics declared an exclusive license agreement for the development of a tumour-activated IL-12 program. Under the deal, Gilead Sciences has agreed to give Xilio $43.5m in…
US-based Boundless Bio will offer 6,250,000 shares for $16 each as the oncology company hears the bell on the Nasdaq market for the first time today (28 March). According…
The European Commission (EC) has approved Otsuka Pharmaceutical Europe and H Lundbeck's Abilify Maintena 720mg/960mg (aripiprazole) for the maintenance treatment of schizophrenia. The treatment is indicated for use in adult…
The US Food and Drug Administration (FDA) has approved Akebia Therapeutics' Vafseo (vadadustat) tablets for anaemia caused by chronic kidney disease (CKD) in adults on dialysis for a minimum of…
Blackstone Life Sciences has entered a development and commercialisation funding agreement with Moderna, committing $750m to support the latter’s influenza programme. The collaboration is part of Blackstone's strategy to support…
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved AstraZeneca's Truqap (capivasertib) plus Faslodex (fulvestrant) for a specific type of breast cancer. The approval is for unresectable or…